Cantor Fitzgerald set a $23.00 target price on Aldeyra Therapeutics (NASDAQ:ALDX) in a research note issued to investors on Wednesday morning. The brokerage currently has a buy rating on the biotechnology company’s stock.
Other equities research analysts have also recently issued reports about the stock. ValuEngine cut shares of Aldeyra Therapeutics from a strong-buy rating to a buy rating in a research report on Monday, July 30th. Zacks Investment Research raised shares of Aldeyra Therapeutics from a sell rating to a hold rating in a research report on Monday, May 21st. Finally, Canaccord Genuity reaffirmed a buy rating and issued a $27.00 target price on shares of Aldeyra Therapeutics in a research report on Friday, August 10th. One investment analyst has rated the stock with a sell rating, one has given a hold rating, three have given a buy rating and one has given a strong buy rating to the company’s stock. Aldeyra Therapeutics presently has an average rating of Buy and a consensus price target of $16.90.
NASDAQ:ALDX opened at $7.90 on Wednesday. Aldeyra Therapeutics has a 12 month low of $4.10 and a 12 month high of $11.90. The company has a current ratio of 8.11, a quick ratio of 8.11 and a debt-to-equity ratio of 0.03.
Aldeyra Therapeutics (NASDAQ:ALDX) last posted its earnings results on Thursday, August 9th. The biotechnology company reported ($0.46) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.43) by ($0.03). analysts anticipate that Aldeyra Therapeutics will post -1.8 EPS for the current fiscal year.
Hedge funds and other institutional investors have recently modified their holdings of the stock. Rhumbline Advisers purchased a new position in Aldeyra Therapeutics during the 2nd quarter valued at about $113,000. Element Capital Management LLC purchased a new position in Aldeyra Therapeutics during the 1st quarter valued at about $123,000. Schwab Charles Investment Management Inc. purchased a new position in Aldeyra Therapeutics during the 2nd quarter valued at about $237,000. Essex Investment Management Co. LLC purchased a new position in Aldeyra Therapeutics during the 2nd quarter valued at about $312,000. Finally, Mesirow Financial Investment Management Inc. purchased a new position in Aldeyra Therapeutics during the 2nd quarter valued at about $327,000. 57.83% of the stock is owned by institutional investors.
Aldeyra Therapeutics Company Profile
Aldeyra Therapeutics, Inc, a biotechnology company, focuses on the development of products for inflammation, inborn errors of metabolism, and other diseases in the United States and internationally. It is developing ADX-102, a small molecule designed to trap and allow for the degradation of aldehydes, as well as ADX-103 and ADX-104 novel candidates for the treatment of noninfectious anterior uveitis, allergic conjunctivitis, dry eye syndrome, sjögren-larsson syndrome, and succinic semi-aldehyde dehydrogenase deficiency.
Read More: Do Tariffs Work?
Receive News & Ratings for Aldeyra Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aldeyra Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.